Incidence and predictors of major gastrointestinal bleeding in patients on aspirin, low-dose rivaroxaban, or the combination: Secondary analysis of the COMPASS randomised controlled trial.
Nauzer ForbesQilong YiPaul MoayyediJackie BoschDeepak L BhattKeith A A FoxJohn W EikelboomPublished in: Alimentary pharmacology & therapeutics (2024)
We established incidences and identified risk factors for GIB in users of low-dose DOACs. Novel risk factors included current or former smoking and diverticulosis. Future studies should aim to validate these risk factors.
Keyphrases
- low dose
- risk factors
- end stage renal disease
- high dose
- chronic kidney disease
- newly diagnosed
- peritoneal dialysis
- study protocol
- venous thromboembolism
- atrial fibrillation
- prognostic factors
- randomized controlled trial
- smoking cessation
- cardiovascular events
- patient reported outcomes
- percutaneous coronary intervention
- patient reported